Microbio is an Australian biotech startup that plans to change the course of pathogen detection. Our novel diagnostic method combines the latest advances in bioinformatics, genomics and molecular microbiology to deliver rapid pathogen detection using qPCR. Developed in collaboration with Australian clinicians, Microbio’s flagship product InfectID-BSI has been designed with clinical decision-making in mind, to… Continue reading Introducing Microbio
News
Microbio Shareholder Rights to Receive Documents
Microbio Shareholder Notice of Rights to Receive Documents
Microbio Expands into Greece with ELTA 90 MGR as Exclusive Distributor
At Microbio, we’re proud to announce our latest step in global expansion – the signing of an exclusive distribution agreement with ELTA 90 MGR, a prominent distributor of advanced medical and laboratory diagnostics, to bring Microbio’s cutting-edge products to the Greek healthcare market. This strategic partnership is a key milestone in Microbio’s global expansion plan… Continue reading Microbio Expands into Greece with ELTA 90 MGR as Exclusive Distributor
Microbio Expands into Italy: LionDx Appointed as Exclusive Distributor
At Microbio, we’re excited to announce our latest milestone – the appointment of LionDx as our exclusive distributor in Italy. This partnership marks a significant step forward in expanding access to our innovative pathogen diagnostic solutions throughout Europe. Enhancing healthcare outcomes with InfectID-BSI™ Our flagship product, InfectID-BSI™, is at the core of this partnership. InfectID-BSI™… Continue reading Microbio Expands into Italy: LionDx Appointed as Exclusive Distributor
ASM Microbe 2024: How molecular diagnostic tests can inform clinical decision-making
Attendees at the American Society for Microbiology (ASM) Microbe 2024 in Atlanta, Georgia are invited to view three posters presented by Microbio Founder and Chief Scientific Officer, Dr Flavia Huygens. If you’re curious about the power of molecular diagnostics to support clinical decision-making in sepsis, a discussion with Dr Huygens is highly recommended! 💡Friday 14… Continue reading ASM Microbe 2024: How molecular diagnostic tests can inform clinical decision-making
Microbio appoints Colin Keating as CEO
Brisbane, 24 October 2023 – Microbio Ltd, an Australian molecular pathogen diagnostics company, is pleased to announce the appointment of Colin Keating as CEO, effective from 1 November 2023. Mr Keating joined Microbio as interim COO in May and assumed the role of interim CEO in early June. Mr Keating’s experience delivering transformation programs at… Continue reading Microbio appoints Colin Keating as CEO